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Abstract
Zinc (Zn) is an essential element for normal brain function; an abnormal Zn homeostasis in brain
and the cerebrospinal fluid (CSF) has been implied in the etiology of Alzheimer’s disease (AD).
However, the mechanisms that regulate Zn transport in the blood–brain interface remain unknown.
This study was designed to investigate Zn transport by the blood–CSF barrier (BCB) in the
choroid plexus, with a particular focus on Zn transporter-2 (ZnT2), and to understand if lead (Pb)
accumulation in the choroid plexus disturbed the Zn regulatory function in the BCB. Confocal
microscopy, quantitative PCR and western blot demonstrated the presence of ZnT2 in the
choroidal epithelia; ZnT2 was primarily in cytosol in freshly isolated plexus tissues but more
toward the peripheral membrane in established choroidal Z310 cells. Exposure of rats to Pb (single
ip injection of 50mg Pb acetate/kg) for 24 h increased ZnT2 fluorescent signals in plexus tissues
by confocal imaging and protein expression by western blot. Similar results were obtained by in
vitro experiments using Z310 cells. Further studies using cultured cells and a two-chamber
Transwell device showed that Pb treatment significantly reduced the cellular Zn concentration and
led to an increased transport of Zn across the BCB, the effect that may be due to the increased
ZnT2 by Pb exposure. Taken together, these results indicate that ZnT2 is present in the BCB; Pb
exposure increases the ZnT2 expression in choroidal epithelial cells by a yet unknown mechanism
and as a result, more Zn ions may be deposited into the intracellular Zn pool, leading to a relative
Zn deficiency state in the cytoplasm at the BCB.
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Introduction
Zinc (Zn) is an essential element for brain development and function.1–3 Zn deficiency
inhibits cell growth and division, while excessive extracellular Zn level can cause cell death,
leading to neuronal degeneration.4–5 Involvement of Zn in Alzheimer’s disease (AD) has
been recognized since the early 1990s. Both amyloid precursor protein (APP) and beta-
amyloid (Aβ) can be characterized as Cu/Zn metalloproteins, with APP in the CSF being
more easily precipitated than Aβ peptides.6 Zn can bind to a specific, cysteine-rich region of
the APP-695 ecto domain.7,8 Noticeably, Zn(II) is the only physiologically available metal
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ion capable of precipitating Aβ at pH 7.4. The exact role of Zn in AD etiology remains
controversial. Some suggest that Zn deficiency is one of the risk factors for AD. Significant
low levels of Zn in serum9 and cerebrospinal fluid (CSF)10 have been found in the patients
with AD. The low Zn extracellular level could be due to Zn interaction withAβ and/or APP;
the binding of Zn with proteins may lead to a depletion of extracellular Zn. An increased Zn
level has been found in the aggregated senile plaques.6,7,11 Some researchers have also
reported that the extracellular Zn is involved in the amyloidopathy and advanced AD.12,13
Clearly, the regulatory mechanisms at the blood, CSF, and brain parenchyma interfaces play
an important role in keeping the homeostasis of Zn in the central nervous system (CNS).
However, limited knowledge is currently available on the Zn regulatory system in brain;
even less is known about how brain controls the transport of Zn by brain barrier systems.
Zinc transporter-2 (ZnT2), a member of the Zn transporters family, is widely expressed in
small intestine, kidney, placenta, pancreas, testis, seminal vesicles, prostate and mammary
gland, and functions to transport Zn from the cytoplasm to the lumen of organelles or the
extracellular compartment so as to reduce the intracellular Zn levels.14–19 Inside cells, ZnT2
has been found highly express in the vesicles and lysosomes.20 The ZnT family possesses a
structure with a long loop ion-binding domain containing histidine residues.21,22 Liuzzi et al.
have clarified that ZnT2 was oriented apically, directly adjacent to the microvilli of the
polarized enterocytes.19 However, whether ZnT2 existed in the blood–brain barrier (BBB),
which separates the blood from brain interstitial fluid, or in the blood-CSF barrier (BCB),
which disconnects the blood from the CSF, remain unknown. Noticeably, the BCB is mainly
located in the polarized choroid plexus in brain ventricles and functions to produce the CSF
and regulate the transport of nutrients and materials including metal ions between blood and
CSF.23–25 Earlier human autopsy data have shown that the curly fibers and tangles
accumulate in the choroid plexus and ependymal layer of AD patients.26 The data in
literature and from our own works have also established that the choroid plexus contains
APP and soluble Aβ, a source of CSF Aβ.27,28
Recently, studies from this group using Tg-SWDI transgenic mice, which genetically over-
express amyloid plaques at age of 2–3 months, show that subchronic exposure to toxic
metal, lead (Pb) causes a significant increase of Aβ in the CSF, brain cortex and
hippocampus. Immunohistochemistry displayed a detectable increase of amyloid plaques in
brains of Pb-exposed animals. Further studies using synchrotron X-ray fluorescence
technique demonstrate a high level of Pb present in amyloid plaques in mice exposed to Pb
in vivo.29,30 These findings support data in the literature that Pb exposure may increase the
risk of AD.31–35 Since Pb poisoning remains one of the major public health concerns among
children and occupational workers,36 and since Pb is known to accumulate in the choroid
plexus,25 it became interesting to learn if Pb accumulation in the choroid plexus may
interact with Zn transport systems and affect Zn homeostasis in the CSF and brain.
The present study was designed to test a novel hypothesis that ZnT2 was expressed in the
BCB in brain choroidal plexus and Pb exposure may affect the function of ZnT2, thereby
interfering with the Zn transport across the BCB. The findings from this study would enrich
the literature on how Zn is transported by the blood–brain–CSF interfaces and whether Pb-
induced amyloid plaque formation has a potential linkage to Zn regulation by the brain
barrier systems. The results shall be of interest to Zn researchers as well as
neurotoxicologists engaged in Pb research.
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Lead acetate (PbAc), β-actin, dithiothreitol (DTT), 2-mer-captoethanol,
phenylmethylsulfonyl fluoride (PMSF), polyacrylamide and tetramethyl-ethylenediamine
(TEMED), dexamethasone (DEX) and the polyclonal anti-rabbit ZnT2 antibody for
immunoblotting were purchased from Sigma Chemicals (St. Louis, MO); Alexa-labeled
secondary antibodies (Invitrogen, NY); enhanced chemiluminescene reagent (ECL) from
Pierce Endogen (Rockford, IL), Mito-tracker from Invitrogen (Carlsbad, CA); and
Dulbecco’s modified essential medium (DMEM), fetal bovine serum (FBS), penicillin,
streptomycin, gentamycin, and 0.25% trypsin EDTA from Gibco (Grand Island, NY). All
reagents were of analytical grade, HPLC grade or the best available pharmaceutical grade.
Animals and Pb administration
Male Sprague-Dawley rats were purchased from Harlan Sprague Dawley Inc. (Indianapolis,
IN). At the time of use, the rats were 10 weeks old weighing 220–250 g. Upon arrival, the
rats were housed in a temperature-controlled room under a 12-h light/dark cycle and allowed
to acclimate for one week prior to experimentation. They had free access to tap water and
pellet Purina semi-purified rat chow (Purina Mills Test Diet, 5755C. Purina Mills,
Richmond, Inc.). The study was conducted in compliance with animal uses regulation and
approved by the Animal Care and Use Committee of Purdue University. PbAc dissolved in
sterile saline was administrated to rats by a single ip injection with 0.1 mL/kg body weight
at the dose of 50 mg PbAc/mL. The daily equivalent volume of sterile saline was given to
the animals in the control group.37–39 Twenty-four hours after the injection, rats were
anesthetized with ketamine/xylazine (75:10mg/kg, l mg/kg ip). Rat brains were dissected to
harvest the choroid plexus tissues from the lateral ventricles for the immunohistochemistry,
quantitative real-time RT-PCR (qPCR) and western blot determinations.
Cell culture and treatments
The choroidal epithelial Z310 cell line was originally developed from murine choroid plexus
by this laboratory. The characteristics, culture and maintenance procedures of this cell line
were described in previous publications.40 In brief, Z310 cells were grown in DMEM
medium containing 10% FBS, 10,000 U penicillin/mL, 10,000 µg streptomycin/mL, 50mg/
mL Gentamicin sulfate, and 10ng/mL EGF), in a humidified incubator with 95% air-5%
CO2 at 37°C.
Autoclaved 5 mM PbAc stocking solution was prepared by dissolving PbAc in sterile
double-deionized water. The cells were treated with the working concentration of 5 µM
PbAc for 24 h to determine localization and expression of ZnT2. Z310 cells were also
treated with 100 nM DEX in the culture medium for 24 h to upregulate the expression level
of ZnT2.41 At the end of the treatments, cells were collected for further protein and total
RNA isolations.
Immunohistochemistry
The glass coverslips were sterilized with 75% ethanol, rinsed and placed in a six-well plate.
The Z310 cells were seeded at a density of 3 × 105/well, allowed to grow for 24 h to achieve
80% confluence, and then treated with 5 µM PbAc and 100 nM DEX for another 24 h. At
the end of treatment, the cells were fixed in 4% paraformaldehyde and permeabilized in
0.1% Triton X-100 at room temperature, followed by three washes with PBS in between
each step. Cells were then blocked with 1% bovine serum albumin (BSA) for 1 h followed
by overnight incubation with polyclonal anti-rabbit ZnT2 primary antibody (1:1000) at 4°C
After a 1 h incubation with Fluor Alexa-488 conjugated secondary antibody (1:1000) at
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room temperature, the glass coverslips were mounted using Gold Anti-Fade reagent
(Invitrogen, Carlsbad, CA) and dried overnight for further observation using the confocal
microscopy.
Confocal microscopic study
To acquire images, prepared slides were mounted on the stage of a Nikon inverted confocal
laser-scanning microscope and viewed through a 60× oil-immersion objective (Plan Apo,
60×/1.40 oil, ∞ 0.17, Ph3 DM), with a 488nm laser line for excitation. Lower laser intensity
was used to avoid photo bleaching. Each slide was examined under reduced, transmitted
light illumination and an area containing undamaged epithelium with underlying vasculature
was selected.
Quantitative real-time RT-PCR
The mRNA level encoding ZnT2 was quantified using qPCR. The total RNA was isolated
from Z310 cells using the TRIzol reagent. An aliquot of 0.5 µg RNA was reverse-
transcribed into cDNA. iTaq Universal SYBR Green Supermix (BioRad, CA) was used for
qPCR analyses. The amplification was run in the CFX connect TM real-time PCR detection
system (BioRad, CA). With an initial 3-min denaturation at 95°C, the amplification program
was followed by 40 cycles of 30 s denaturation at 95°C, 10 s gradient 55.0 to 65.0°C and 30
s extension at 72°C. Each real-time RT-PCR reaction was run in triplicate. The forward and
reverse primers for the ZnT2 gene were designed using Primer Express 3.0 software.
Primers sequences for rat ZnT2 used in this study were forward primer 5’-AAG TAC GTG
GAC CCC ATC TG-3’and a reverse primer 5’-CCC TTC CAT GAG AAC CAA GA-3’
(GenBank accession no. NM_052803.1). And the rat glyceraldehydes-3-phos-phate
dehydrogenase (GAPDH), used as an internal control, had a forward primer 5’-CCT GGA
GAA ACC TGC CAA GTAT-3’ and a reverse primer 5’-AGC CCA GGA TGC CCT TTA
GT-3’ (Genbank Accession No. NM_017008).42,43 The relative differences in gene
expression between groups were expressed using cycle time (Ct) values; these Ct values of
interested genes were first normalized with the GAPDH of the same sample, and then the
relative differences between control and treatment groups were calculated and expressed as
relative increases, setting the control as 100%.
Western blot analyses
Total cellular proteins from Z310 cells were extracted in homogenization buffer containing
20mM Tris, pH 7.5, 5mM EGTA, 1% Triton X-100, 1% SDS, Protease Inhibitor Cocktail
(Calbiochem, San Diego, CA). Samples were sonicated and quantified for protein
concentrations using a Bradford assay. A volume of protein extracts (100 µg of protein) was
mixed with an equal volume of 2× sample buffer, loaded on a 12% SDS-PAGE gel,
electrophoresed and transferred to a polyvinylidene difluoride (PVDF) membrane. The
membrane was blocked with 5% milk in Tris-buffered saline with Tween 20 and incubated
with a primary antirabbit polyclonal ZnT2 (42kDa) antibody (1:100) at 4°C overnight,
followed by a stain with a horseradish-peroxidase-conjugated goat anti-rabbit IgG antibody
(1:3000) at room temperature for 1 h and developed using ECL. β-actin (42 kDa) was used
as an internal control. The optical density (OD) of the blot band intensity was further
quantified using Image J and reported in the OD ratio of ZnT2/β-actin.
Cellular Zn retention study
Z310 cells were seeded in 6-well plates at a density of 3 × 105 cells/well for 24 h, followed
by the treatments with 5 µM PbAc and 100 nM DEX for an additional 24h. At the end of the
treatments, cells were incubated with final concentration of 3 µM ZnCl2 in the Hank’s
balanced salt solution (HBSS) for 1 h and then harvested followed by three washes with
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PBS to remove excessive Zn. Intracellular Zn levels were determined using atomic
absorption spectrophotometry (AAS) after the measurement of protein quantity. All samples
were digested with concentrated nitric acid in an oven at 55°C, overnight. A Varian Spectra
AA-20 Plus GTA-96 flameless graphite furnace AAS was used to quantify Zn
concentrations in the Z310 cells. Digested samples were diluted with 1.0% (v/v) HNO3 for
Zn measurement in order to keep the reading within the concentration range of the standard
curve. The ranges of calibration standards were 0–2.5 µg/L for Zn and the detection limits
for Zn was 0.9ng/mL of the assay solution.
Two-chamber transwell system using primary choroid plexus cells
The method to culture primary choroidal epithelial cells has been described in previous
publications in this laboratory27,44–46 Rats aged four weeks were sacrificed to harvest
choroid plexus tissues. These tissues were digested in HBSS containing 0.2% pronase at
37°C for 10–15 min, followed by two washes with HBSS, and then re-suspended in growth
DMEM medium containing 10% FBS, 100 units/mL penicillin, 100 µg/mL streptomycin,
0.25 µg/mL amphotericin, 100µg/mL gentamycin, and 10ng/mL EGF. A 20-gauge needle
was used to pass cells through 14–15 times to ensure adequate cell separation for seeding.
Cells stained with 0.4% Trypan blue were counted under a light microscope to determine the
cell numbers; the cells were then seeded on 35-mm Petri dishes (pre-coated with 0.01%
collagen) at a density of 2–3 × 105 cells/mL. The cultured cells were maintained at 37°C
with 95% air-5% CO2 in a humidified incubator without disturbance for at least 48 h. The
growth medium was replaced three days after the initial seeding and every two days
thereafter.
After cultured in dishes for 7–10 days, the cells were transferred to the inner chamber of a
Transwell transport device. The inner chamber, also known as the apical chamber, is
immersed in the outer chamber. An aliquot of 0.8 mL cell suspension (10 × 105 cells/mL for
initial seeding) was added to the inner chamber and 1.2mL of medium was added to the
outer chamber. The transepithelial electrical resistance (TEER), an indicator of the tightness
of the barrier, was used to track the formation of a cellular monolayer between the inner and
outer chambers. The TEER value was measured every other day by an Epithelial Volt-
Ohmmeter (EVOM, World Precision Instruments, Sarasota, FL) until the resistance reached
50–60 Ω/cm2. The same twochamber system without cells was used as the blank and its
background was subtracted from the measured TEER. When the cells grew to a confluence,
the surface level of the medium in the inner chamber was roughly 2 mm above the outer
chamber. This in vitro system mimicking the BCB has been used in our previous
studies.27,37,46–48
In vitro transepithelial transport of Zn
To investigate the transport direction of Zn across the BCB, the primary cells cultured in the
Transwell devices were randomly divided into three groups: the control group without any
treatment, the Pb-exposed group (5 µM PbAc, 24h), and the DEX-induced group (100nM
DEX, 24h). At the end of treatment, an aliquot of 0.8 mL HBSS containing the mixture of
ZnCl2 and 14C-sucrose to the final concentrations of 3 µM ZnCl2 and 0.1 µCi/mL 14C-
sucrose was added to the inner chamber (donor chamber), and an aliquot of 1.2-mL HBSS
was added to the outer chamber (receiver chamber). A series of time points
(0,5,10,15,30,60,90 min, and 2, 3, and 4 h) was set for sample collection. At each time, an
aliquot of 10 µL medium from both chambers was collected and replaced with an equal
volume of the counterpart medium. The concentration and radioactivity were measured in
the outer chamber to determine the efflux of Zn from the CSF to blood. Zn concentrations of
all samples were measured using AAS. To count the 14C-sucrose, the samples were mixed
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with Eco-lite scintillation cocktail and counted on a Packard Tr-Carb 2900 TR Liquid
Scintillation Analyzer.
To determine the permeability constants for Zn and C-sucrose transport across the cellular
monolayer, the data within the linear range of the time course were used for linear
regression analyses. The slope (Zn ng/mL/min and 14C-sucrose dp.m./mL/min) of each
dataset was used to calculate the total and blank permeability coefficients in equation (1):
(1)
where PT is the total (cell monolayer + membrane) permeability coefficient (cm/min); PB is
the blank permeability coefficient (cm/min); VR is the volume of the receiver (ml or cm3); A
is the surface area of transport membrane in the inner chamber (cm2); CD is the
concentration in donor chamber (mg/mL); and ΔCR/Δt is the changes of concentration in the
receiver over a fixed time period (mg/mL/ min). Thus, the permeability or flux coefficient of
metals (PE) can be obtained from equation (2):
(2)
where PE is the permeability coefficient of Zn or 14C-sucrose transport across the epithelial
barrier.
Statistical analysis
Statistical analyses of the differences between groups were carried out by one-way ANOVA
with post hoc comparisons by Dunnett’s test or Student t-tests using SPSS for Windows
(version 19.0). All data are expressed as mean±SD. The differences between two means
were considered significant if p values were equal to or less than 0.05.
Results
Expression of ZnT2 in the choroid plexus tissues and effects of in vivo Pb exposure
To determine the existence of ZnT2 in the BCF barrier, the choroid plexus tissues from rat
lateral ventricles were dissected and stained with ZnT2 primary antibody. As shown in
Figure 1(A/a), ZnT2 was distinctly expressed in the choroid plexus and primarily
concentrated close to the apical border with a small portion along the basolateral membrane
in the choroidal epithelial cells.
After rats received a single ip injection of 50mg PbAc/kg for 24h, it was interesting to
observe much stronger intensities of ZnT-2 associated fluorescent signals at the apical
microvilli surface of choroid plexus epithelia than the control tissue (Figure 1A/d). This
finding prompted us to investigate and quantify Pb effect on ZnT2 expression. The qPCR
and western blot were used quantify the mRNA and protein expression levels of ZnT2,
respectively, in the choroid plexus tissue collected from Pb-exposed and control rats. The
mRNA level of ZnT2 as normalized by the housekeeping gene GAPDH was significantly
increased to about 20% following Pb exposure when compared with the control (P < 0.05)
(Figure 1B). Consistent with qPCR results, the western blots also showed the ZnT2 protein
expression in plexus tissues collected fromanimals treated with Pb was 46% higher than that
in control tissues (P<0.05) (Figure 1(C) and (D)).
Fu et al. Page 6













Expression of ZnT2 in choroidal Z310 cells following Pb exposure, in vitro
To study Pb effect on ZnT2, it was necessary to choose a Pb concentration that did not cause
the substantial cell killing. The cells were incubated with 5, 100, and 250 µM PbAc for 24 h
and cell viability was determined by counting the live cell numbers. The data in Figure 2(a)
showed that at the concentrations of 100 and 250 µM PbAc treatments caused a substantial
reduction in cell numbers under the light microscope. The total cell numbers were
significantly reduced in these two dose groups while they were unchanged in the group
treated with 5 µM PbAc (Figure 2b). Thus, in the subsequent in vitro experiments, PbAc
concentration of 5 µM was used.
When the Z310 cells were stained with the ZnT2 primary antibody, the confocal
microscopic observation revealed that ZnT2 was present in choroidal Z310 cells. Similar to
the choroid tissue, the stains for ZnT2 in cultured control cells, while mainly in the
cytoplasm, were distributed proximally to the plasma membrane (Figure 3A/a). Following
treatment of Z310 cells with 5 µM PbAc for 24h, the ZnT2 fluorescent signals were visibly
stronger in Pb-treated cells than controls and highly concentrated close to the plasma
membrane with a small amount scattered in the cytosolbut not in the nuclei (Figure 3A/d).
The qPCR analyses showed about 60% increase in ZnT2 mRNA expression in Pb-treated
cells as compared with the control (P <0.05) (Figure 3B). The protein expression level of
ZnT2 was also significantly increased following Pb exposure when compared with the
control (P < 0.01) (Figure 3(C) and (D)). These results demonstrate that ZnT2 exists in the
choroidal Z310 cells and Pb exposure appears to upregulate the expression of ZnT2.
As a positive control, we chose the glucocorticoid analog DEX to verify the expression of
ZnT2 in the Z310 cells, since DEX is known capable of upregulating the expression of ZnT2
in various cell lines (i.e. rat AR42J acinar cells). After the Z310 cells were incubated with
100 nM DEX for 24h, confocal images revealed a greatly increased fluorescent intensityin
the treated cells (Figure 4A). Noticeably, the increased signals were not only highly
concentrated along the cell membrane but also around the central nucleus. Both qPCR and
western blot measurements verified significant increases in ZnT2 mRNA (~40%) and
protein expression (~70%), respectively, in cells treated with DEX than control cells
(P<0.01) (Figure 4(B) to (D)). The data suggest that DEX effectively increases the
expression of ZnT2 in choroidal epithelial cells as it does to other cell types.
Cellular Zn concentrations after in vitro Pb treatment
Since ZnT2 functions to export the intracellular Zn to extracellular matrices, we
hypothesized that the intracellular Zn concentration in Pb-treated Z310 cells would be
decreased due to the elevated ZnT2 expression. To test this hypothesis, Z310 cells were
incubated with 5 µM PbAc and 100 nM DEX (as a positive control) for 24 h, followed by
incubation with the HBSS containing 3 µM ZnCl2 for 1 h. After thoroughly washing the
cells with PBS to remove the extracellular Zn, the cells were collected for AAS analysis of
cellular Zn concentrations. The results in Figure 5 revealed that the intracellular Zn
concentration in control cells was 631 ng Zn/g protein, which was significantly higher than
those in Pb-treated (460 ng Zn/g protein, P <0.01) or DEX-treated cells (516 ng Zn/g
protein, P < 0.05), suggesting that the increased expression of ZnT2 may be one of the
potential mechanisms that led to the deficiency of intracellular Zn in choroidal cells.
Transepithelial Zn transport studies
The primary culture of choroid plexus epithelial cells was used in a two-chamber Transwell
system to determine the Pb effect on the transepithelial transport of Zn. The formation of a
complete monolayer barrier between two chambers was noticed about 12 days in the culture
by microscope observation and also by the TEER values, which reached about 50–65 Ω/cm
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(Figure 6A). The TEER value was significantly decreased in cells treated with 5 µM Pb, so
were cells treated with DEX (Figure 6B); however, this reduction in TEER values did not
seem to cause the structural leakage of the barrier, since the permeability constant (PE)
values for the space marker C-sucrose did not change in Pb- and DEX-treated cells (Table
1).
In the control group, when Zn was added to the donor (inner) chamber and monitored in the
receiver (outer) chamber, the transport of Zn across the BCB after correcting for the space
marker of 14C-sucrose had the transepithelial permeability constant of PE=(18.34 ±2.26) ×
10−4 cm/min (Table 1). In the Pb- and DEX-exposed groups, the PE values of Zn across the
monolayer were (35.50 ± 6.38) and (25.65 ±6.79) × 10−4 cm/min, respectively, which were
significantly increased as compared with the control (Table 1). The data appeared to suggest
that Pb exposure decreased cellular retention of Zn in the BCB and increased the Zn
transport across the BCB; the effect may be a consequence of the elevated intracellular
ZnT2 in choroidal epithelial cells following the Pb exposure.
Discussion
ZnT2 was first found in the membranes of intracellular vesicles in the Zn-sensitive BHK cell
line,49 intestine epithelia, and pancreatic acinar cells14, where ZnT2 functions to confer
resistance to Zn by facilitating Zn transport from the cytosol into the vesicle called
zincosome for sequestration in order to maintain the cellular Zn homeostasis.50 The results
presented in this study clearly demonstrate that ZnT2 exists in the choroid plexus, where the
BCB is located. In freshly isolated plexus tissues, ZnT2 is present proximally to the apical
brush border and basolateral membrane of the choroidal epithelia. Similarly, in the
established choroidal epithelial Z310 cells, ZnT2 also appears to distribute peripherally
toward the plasma membrane. These findings were consistent with previous studies which
also observed apical localizations of ZnT2 isoforms in rat mammary and intestine epithelial
cells.14,51 Pb exposure, either in vivo or in vitro, apparently induces the ZnT2 expression in
the choroid plexus; consequently Pb exposure causes intracellular Zn deficiency.
Earlier reports in literature have shown the presence of a number of Zn transporters in rodent
choroid plexus including ZnT1, ZnT3, ZnT4, ZnT6, ZnT7, zip1, and zip4.52–54 Studies by
Bobilya et al. show the expression of ZnT2 in a BBB model using porcine brain capillary
endothelial cells (BCEC); when the intracellular Zn concentration was maintained at a high
level, the ZnT2 expression was elevated, suggesting that ZnT2 may be involved in Zn
transport by the BBB and play a role in maintaining brain Zn homeostasis.55 The current
studies by using confocal microscopy, qPCR and western blot demonstrated the presence of
ZnT2 in rat choroid plexus tissues and choroidal Z310 cell line. Thus, in addition to the
BBB, the BCB appears to play a role in regulating Zn transport between the blood and CSF.
Our observation raises more interesting questions for future investigation. For example,
what is the relative contribution of the BBB and BCB in regulating brain Zn concentrations?
To which direction do the BBB and BCB transport Zn molecules? How do the function and
efficacy of each Zn transporter in the BCB in their own unique role regulate the Zn uptake,
storage and transpassing in or across the barrier?
Existing literature has established that Pb exposure interferes with the metabolism of Zn in
blood, kidney, liver, spleen, testes, bone and brain, leading to a decreased cellular Pb
accumulation.56–58 Investigations in occupationally Pb-exposed workers also show a
significant decrease in blood Zn levels in Pb-exposed workers.59,60 In contrast, increased
dietary intake of Zn can compete with Pb for binding sites on a metallothionein-like protein
in the gastrointestinal tract, thereby reducing Pb absorption and subsequently decreasing Pb
toxicity.61–64 As Zn is a required cofactor for several enzymes such as metallothionein, δ-
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aminolevulinic acid dehydratase (δ-ALAD) and superoxide dismutase (SOD), Pb may
interact with Zn in these enzymes for the similar chemical characteristics of both divalent
metals. Our current data clearly showed that exposure to Pb, either in vivo or in vitro, caused
a significant increase of ZnT2 in the BCB. The precise mechanism by which Pb exposure
induces the upregulation of ZnT2 remains elusive. As Pb exposure induced the expression of
ZnT2, presumably, more Zn may be shifted into intracellular vesicles resulting in a state of
relative Zn deficiency in cells. An indepth investigation is thus warranted for future
mechanistic exploration. As the function of ZnT2 is to export Zn, it is reasonable to
postulate that increased ZnT2 may expel the intracellular Zn and result in a reduction of Zn
within BCB cells. Our in vitro Zn retention study proved that incubating primary choroidal
epithelial cells with Pb led to a significant reduction of cellular Zn. Hence, Pb effect on
ZnT2 appears to induce, at least in part, the cellular deficiency of Zn in the choroid plexus.
Since the BCB separates two distinct fluid compartments, i.e. the blood and CSF, it became
interesting to see whether Pb-induced ZnT2 upregulation ultimately affected the Zn
transepithelial transport. Our two-chamber Transwell experiments with primary culture of
choroidal epithelial cells showed a significant increase (but not decrease) of Zn transport
across the monolayer of choroidal epithelia, suggesting that the major transport orientation
of ZnCl2 across the BCB is in an efflux manner from the CSF to the blood circulation. Two
early studies found that Zn uptake into the rat brain across cerebral capillaries was about 20
nmol/day/brain, while that across the choroid plexus was less than 0.2nmol/day/brain, as a
consequence of the low influx rate across the BCB, the normal Zn level in CSF is 0.15 µM,
only accounts for about 1% that of plasma.65–69 These findings suggest that the major
supply path for Zn is via the BBB, whereas the choroid plexus may involve in a slow supply
for Zn to the brain.70–72 ZnT2 acts to transport Zn molecules into intracellular vesicles for
storage. The work by Bobilya and his colleagues shows evidence that ZnT2 in the BBB may
sequester Zn into intracellular vesicles and therefore limit Zn transport across the BBB.55
From the clinical point of view, a significantly lower CSF Zn concentration has been found
in AD patients than that of matched controls.10 Constantinidis and colleagues also
hypothesize that the formation of neurofibrillary tangles observed in AD patients could be
due to the deficiency of Zn-containing enzymes including DNA metabolizing Zn enzymes,
glutamate dehydrogenase,73,74 SOD, carbonic anhydrase, and lactate dehydrogenase. Since
the BCB produces and regulates the bulk of CSF, it would be highly interesting to explore
how exactly the BCB regulates the Zn homeostasis in the CSF as well as brain extracellular
fluid compartments.
In summary, this study provides the evidence of the presence of ZnT2 in the cytosol of
choroidal epithelial in the BCB, and ZnT2 appears to expel intracellular Zn molecules to
extracellular space, hence transporting Zn across the BCB. Pb exposure significantly
upregulates ZnT2 mRNA and protein expression; expelling Zn out of the cells by ZnT2 may
subsequently lead to anintracellular Zn deficiency. The questions as to how ZnT2 regulates
Zn transport across the BCB, how Pb exposure, via interference with Zn transport by the
BCB, may affect Zn homeostasis in brain, and how it may be relevant to the development of
AD would become interesting research topics for future investigation.
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Expression of ZnT2 in choroid plexus tissue and effect of Pb exposure. A(a–c). Choroid
plexus tissues were dissected from the lateral ventricles. A(d–f). For in vivo Pb exposure,
animals received a single ip injection of 50 mg PbAc for 24 h. A(a) and A(d) show the ZnT2
green fluorescent signal; A(b) and A(c) show the DIC mages; A(c) and A(f) are the merged
images of ZnT2 fluorescent signal and DIC. (B) qPCR quantitation of ZnT2 mRNA
expression in the choroid plexus. Data represent mean ± SD, n=6, *P < 0.05, as compared
with the control. (C) Western blot analysis of ZnT2 in the choroid plexus. β-actin was used
as the house-keeping protein. (D) Quantification of western blot was expressed as the OD
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ratio of ZnT2/β-actin. Data represent mean ± SD, n=3, *P < 0.05 as compared with the
control. (A color version of this figure is available in the online journal.)
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Effect of Pb exposure on cultured Z3310 cells. (A) Cells were treated with 5,100, and 250
µM Pb for 24 h. The cell morphology appeared normal in the 5 mM Pb group, while the cell
numbers were visibly lower in higher Pb dose groups. (B) Dose-response relationship
between Pb treatment and total cell counts. Data represent mean ± SD, n=6, **P < 0.01 as
compared with the control
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Presence of ZnT2 in choroidal Z310 cells and effect of Pb exposure. A(a–c)) Control cells;
A(d–f) Pb-treated Z310 cells. A(a) and A(d) show the ZnT2 green fluorescent signal; A(b)
and A(c) show the DIC images; A(c) and A(f) are the merged images of ZnT2 fluorescent
signal and DIC. (B) qPCR quantitation of ZnT2 mRNA expression. Data represent mean ±
SD, n=6, **P < 0.01 as compared with the control. (C) Western blot analysis of ZnT2 in
Z310 cells. β-actin was used as the internal control. (D) Western blot quantification. Data
represent mean±SD, n=3, *P<0.01, as compared with the control. (A color version of this
figure is available in the online journal.)
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Upregulation of ZnT2 following DEX exposure. A(a–c)Control images; A(d–f) Pb-treated
Z310 cells. A(a) and A(d) show the ZnT2 green fluorescent signal; A(b) andA(c) show the
DIC images; A(c) and A(f) are the merged images of ZnT2 fluorescent signal and DIC. (B)
qPCR result of increased ZnT2 mRNA expression following DEX exposure. Data represent
mean±SD, n=6, **P<0.01 as compared with the control. (C) Western blot result of ZnT2
and β-actin. (D) Quantification of western blot. Data represent mean±SD, n=4, *P<0.01, as
compared with the control. (A color version of this figure is available in the online journal.)
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Decreased intracellular Zn level following Pband DEX exposure. Cells were incubated 5 µM
PbAc and 100nM DEX for 24 h followed by 1 h incubation with 3 µM ZnCl2. The
intracellular Zn concentration was determined by AAS. Result shows the intracellular Zn
concentrations (ng Zn/g protein) in the control, Pb- and DEX-treated groups. Data represent
MD ± SD, n=6, *P < 0.05, **P < 0.01, as compared with the control
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Transwell permeability as affected by treatment of Pb and DEX. (A) Primary choroid plexus
epithelial cells were cultured in the inner chamber of the Transwell device for 12 days and
the TEER values were measured to track the formation of the monolayer. (B) After the
monolayer barrier was formed, the primary cells were treated with 5 µM PbAc and 100 nM
DEX for 24 h. At the end of the treatment, the TEER values were measured. Data represent
MD ± SD, n=4–6, *P < 0.05, as compared with the control.
Fu et al. Page 20

























Fu et al. Page 21
Table 1




Control 12.24 ±0.66 18.34 ±2.26 1.50 ±0.08
PbAc (5 µM) 12.54±0.27 35.50 ±6.83* 2.83±0.31*
DEX (100nM) 12.43±0.51 25.65 ±6.79** 2.06 ±0.24**




P < 0.05 as compared to the control. Treatment conditions are described in the Methods section.
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